Public



Luxembourg, 14 December 2022

# **Environmental and Social Data Sheet**

Overview		
Project Name:	COVID-19 VACCINE VOLUME A	LLOCATION III
Project Number:	2022-0088	
Country:	Global	
Project Description:	A liquidity facility to support the monetization of grants by donor countries to Gavi in order to fund immunisation campaigns and health strengthening activities.	
EIA required:		no
Project included in Carbon Footprint Exercise <sup>1</sup> :		no

Project included in Carbon Footprint Exercise<sup>1</sup>: no (details for projects included are provided in section: "EIB Carbon Footprint Exercise")

# **Environmental and Social Assessment**

In the near term, the Project directly supports the purchase and supply of successful SARS-CoV-2 vaccines to LMICs, through full delegation to COVAX. And in the longer term when the COVAX facility will be integrated into Gavi<sup>2</sup>'s business, the project will support sustainable immunisation campaigns addressing over 18 infectious diseases in Gavi eligible countries. The project aims to increase immunisation coverage in low-income countries, harness vaccine supply security and provide sustainable immunisation programs.

# **Environmental Assessment**

The activities to be financed under the project do not fall under Annex I or Annex II of the EIA Directive 2014/52/EU amending Directive 2011/92/EU.

The project is considered to be aligned with the Paris Agreement, as defined in the EIB Climate Bank Roadmap.

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

# Social Assessment, where applicable

The project, if successful, is expected to lead to important social benefits stemming from its focus on increasing immunisation in children, leading to important spillover effects such as the

<sup>&</sup>lt;sup>1</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO2e/year absolute (gross) or 20,000 tonnes CO2e/year relative (net) – both increases and savings.

 $<sup>^{2}</sup>$  Gavi is an international organisation created in 2000 to improve access to new and underused vaccines for children living in the world's poorest countries.

facilitation of touchpoints between families and health services through vaccination and other important economic benefits.

The project is expected to have a significant impact on gender equality. The promoter is committed to increasing immunisation coverage by supporting countries to overcome gender-related barriers to accessing immunisation services and promoting equity of access for all genders to immunisation and related health services that respond to their different needs. These actions are enforced through a specific gender policy.

#### **Other Environmental and Social Aspects**

GAVI has multiple policies in place including their transparency and accountability policy which ensures that all GAVI support at country level is managed in a transparent and accountable manner, through systems that include appropriate oversight mechanisms, and that the support is used according to the programme objectives as outlined in individual country agreements.

The Bank will require the Promoter to take all the requisite measures, to ensure compliance with the relevant and applicable legislation as well as with the EIB's environmental and social standards.

#### Paris alignment of the project

With the project, it is considered to be aligned with both low carbon and resilience goals and the policies set out in the Climate Bank Roadmap.

#### **EIB Paris Alignment for Counterparties (PATH) Framework**

The counterparty and its Head of Group is in scope

# **Conclusions and Recommendations**

The project concerns investments in vaccines, activities for which do not fall under Annex I or Annex II of the EIA Directive.

The activities undertaken in the project aim to result in new and improved vaccine access with a positive impact on healthcare. Therefore, if the project is successful, it is expected to have a positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects.